主题:Loss

+ 关注 ≡ 收起全部文章

New Hair Loss Gene Is Identified

April 14, 2010 -- A gene responsible for a rare hair loss disorder may also play an important role in male pattern baldness, according to a new study.

Researchers have identified a genetic mutation involved in hypotrichosis simplex, a hereditary hair loss disorder that affects less than 200,000 Americans. The disorder causes hair follicle miniaturization, a process in which hair follicles shrink and narrow, and thick hair is replaced by fine, downy "peach fuzz" hair.

But researchers say that the same process is also a key component of male pattern baldness.

"The identification of this gene underlying hereditary hypotrichosis simplex has afforded us an opportunity to gain insight into the process of hair follicle miniaturization, which is most commonly observed in male pattern hair loss or androgenetic alopecia,"?says researcher Angela M. Christiano, PhD, professor of dermatology and genetics and development at Columbia University Medical Center, in a news release.

The study, published in Nature, highlights the role of a mutated version of the gene APCDD1 in hair follicle biology.

Previous research has already linked the gene to other hair loss disorders, but in this study researchers found the mutated gene inhibits a signaling pathway involved in hair growth.

By learning more about this pathway, known as the Wnt pathway, researchers say the discovery may lead to new and improved treatments for male pattern baldness and other hair loss disorders.

"We have at last made a connection between Wnt signaling and human hair disease that is highly significant," says Christiano. "And unlike commonly available treatments for hair loss that involve blocking hormonal pathways, treatments involving the Wnt pathway would be non-hormonal, which may enable many more people suffering from hair loss to receive such therapies."

Your body is your temple. Are you treating it as well as you should? Get the latest on men's health in the WebMD Men's Health newsletter.

日期:2010年4月15日 - 来自[Health News]栏目

Loss of the High-Affinity Pentamidine Transporter Is Responsible for High Levels of Cross-Resistance between Arsenical and Diamidine Drugs in African Trypanos

【关键词】  Loss

    Treatment of many infectious diseases is under threat from drug resistance. Understanding the mechanisms of resistance is as high a priority as the development of new drugs. We have investigated the basis for cross-resistance between the diamidine and melaminophenyl arsenical classes of drugs in African trypanosomes. We induced high levels of pentamidine resistance in a line without the tbat1 gene that encodes the P2 transporter previously implicated in drug uptake. We isolated independent clones that displayed very considerable cross-resistance with melarsen oxide but not phenylarsine oxide and reduced uptake of [3H]pentamidine. In particular, the high-affinity pentamidine transport (HAPT1) activity was absent in the pentamidine-adapted lines, whereas the low affinity pentamidine transport (LAPT1) activity was unchanged. The parental tbat1-/- line was sensitive to lysis by melarsen oxide, and this process was inhibited by low concentrations of pentamidine, indicating the involvement of HAPT1. This pentamidine-inhibitable lysis was absent in the adapted line KO-B48. Likewise, uptake of the fluorescent diamidine 4',6-diamidino-2-phenylindole dihydrochloride was much delayed in live KO-B48 cells and insensitive to competition with up to 10 µM pentamidine. No overexpression of the Trypanosoma brucei brucei ATP-binding cassette transporter TbMRPA could be detected in KO-B48. We also show that a laboratory line of Trypanosoma brucei gambiense, adapted to high levels of resistance for the melaminophenyl arsenical drug melarsamine hydrochloride (Cymelarsan), had similarly lost TbAT1 and HAPT1 activity while retaining LAPT1 activity. It seems therefore that selection for resistance to either pentamidine or arsenical drugs can result in a similar phenotype of reduced drug accumulation, explaining the occurrence of cross-resistance.

    Trypanosoma brucei subspp. are protozoan parasites that cause human African trypanosomiasis (i.e., sleeping sickness) and the corresponding veterinary condition in livestock. Treatment of both the human and livestock diseases depends on a very small set of mostly very old drugs. The first-line treatment for the late stage of both West African and East African human African trypanosomiasis is melarsoprol, an organoarsenic compound of the melaminophenyl arsenical class, introduced in 1949 (Jannin and Cattand, 2004). A similar but water-soluble melaminophenyl arsenical, melarsamine hydrochloride (Cymelarsan), is increasingly used for animal trypanosomiasis. Early-stage West African sleeping sickness is routinely treated with the diamidine drug pentamidine, introduced in 1937 (Jannin and Cattand, 2004). The corresponding widely used veterinary diamidine is diminazene aceturate (Berenil). The only new trypanocide to be developed in recent decades, DB75, is also a diamidine and currently in clinical trials as an orally available prodrug.

    It has been known for decades that cross-resistance between melaminophenyl arsenicals and diamidine drugs sometimes occurs (Fulton and Grant, 1955; Williamson and Rollo, 1959), but cross-resistance patterns can be unpredictable (Williamson, 1970). Kaminsky and Mäser (2000) distinguished six distinct resistance profiles in Trypanosoma brucei brucei laboratory strains and field isolates, presumably an indication that multiple factors determine (the level of) resistance to the various drugs. They also noted that some resistance profiles seem to be associated with either field or laboratory-induced resistance.

    Some progress has been made in understanding drug resistance mechanisms in trypanosomes. The important role of the T. brucei AT1/P2 purine transporter in the accumulation of melaminophenyl arsenical compounds and diamidines is now well understood (Carter and Fairlamb, 1993; Mäser et al., 1999; De Koning, 2001a; Delespaux and De Koning, 2007). The loss of TbAT1/P2 alone was shown to be sufficient for high levels of diminazene aceturate resistance in T. brucei brucei and Trypanosoma evansi (De Koning et al., 2004; Witola et al., 2004). However, the deletion of the TbaT1 gene produced only minor loss of sensitivity to pentamidine and melaminophenyl arsenicals (Matovu et al., 2003). Thus, the action of some diamidines relies (almost) exclusively on TbAT1/P2 for access to intracellular targets, whereas other diamidines, as well as melaminophenyl arsenicals, have at least one additional route of entry.

    We have shown previously that adenosine-insensitive uptake of [3H]pentamidine in T. brucei brucei is mediated by two discrete transport activities: a low-affinity pentamidine transporter [LAPT1 (De Koning and Jarvis, 2001)] and a high-affinity pentamidine transporter [HAPT1 (De Koning, 2001b)]. Although this seems to explain why clinical pentamidine resistance has not established itself, despite the many decades of intensive use (for review, see Bray et al., 2003), it was not clear whether high levels of pentamidine resistance might ensue with the consecutive loss of TbAT1/P2 and either HAPT1 or LAPT1. Nor is it yet clear why the tbat1-/- line did not display an appreciable level of resistance to melaminophenyl arsenical drugs (Matovu et al., 2003). It has been argued that higher levels of arsenical resistance in trypanosomes could be the result of the (over)expression of an ABC-type transporter of the multidrug resistance type, TbMRPA. Overexpression of this transporter in T. brucei brucei does induce 10-fold resistance to melarsoprol in vitro (Shahi et al., 2002). Arsenical resistance attributed to loss of TbAT1/P2 and overexpression of TbMRPA were shown to be additive (Lüscher et al., 2006). However, TbMRPA overexpression did not lead to arsenical resistance in vivo, and TbMRPA overexpression could not be demonstrated in melarsoprol-resistant trypanosome isolates from patients with sleeping sickness (Alibu et al., 2006).

    In the current article, we address the outstanding questions concerning diamidine and arsenical resistance using Trypanosoma brucei lines adapted to high levels of pentamidine and cross-resistant to melaminophenyl arsenicals. We now provide a model for the biochemical basis of cross-resistance between melaminophenyl arsenicals and the diamidines. The model predicts that HAPT1, together with TbAT1, may be a key determinant for arsenical resistance in African trypanosomes, providing a hypothesis that should now be validated on clinical isolates from patients refractory to melarsoprol.

    Trypanosomes and Cultures. Growth of bloodstream trypanosomes in culture was performed using HMI-9 medium (BioSera Ltd., East Sussex, UK) (Hirumi and Hirumi, 1989) supplemented with 2 mM -mercaptoethanol and 10% fetal bovine serum at 37°C, in a 5% CO2 atmosphere. For transport assays, trypanosomes were grown in adult female Wistar rats and isolated from infected blood as described previously (De Koning and Jarvis, 1997). The cloned Trypanosoma brucei gambiense type 2 stock STIB 386 and the derived melarsamine hydrochloride-resistant clone 386MelCyR (hereafter called 386Ms and 386Mr) were a kind gift of Professor C.M.R. Turner (University of Glasgow). The adaptation of 386Ms to high levels of melarsamine hydrochloride has been described elsewhere (Scott et al., 1996). The T. brucei brucei clone s427 (MiTat 1.2/221) was used to derive the tbat1-/- line (Matovu et al., 2003) and the pentamidine-adapted clonal line WT-D24. tbat1-/- was also adapted to higher levels of pentamidine resistance, generating the clonal lines KO-B6, KO-D6, KO-B48, and KO-D48. Clonal populations were generated by limiting dilution. Cell densities were assessed using a hemocytometer and phase-contrast microscope. The New York line of T. brucei brucei (Wirtz et al., 1999) and the derived MRPA overexpressing line NY-mrpa have been described previously (Lüscher et al., 2006). Overexpression was induced (NY-mrpa+) or repressed (NY-mrpa-) by the inclusion or omission, respectively, of 1 µg/ml tetracycline in the culture medium.

    Transport Assays. Transport assays were performed exactly as described previously (Wallace et al., 2002). In brief, trypanosomes were isolated from blood taken from infected Wistar rats by DEAE-52 (Whatman, Maidstone, UK) anion exchange chromatography, washed into assay buffer, and resuspended at 2 x 108 cells/ml at room temperature. In a minority of cases, trypanosomes for transport assays were cultured in complete HMI-9 medium. Aliquots (100 µl) of bloodstream trypanosomes in assay buffer were mixed with an equal volume of buffer containing radiolabel and sometimes inhibitor, at twice the final concentration, initiating transport. Transport was terminated by the addition of 1 ml of ice-cold buffer containing unlabeled permeant at a saturating concentration (2 mM for pentamidine) followed by rapid centrifugation through an oil layer, separating cells from radiolabel not internalized. Transport values are expressed as picomoles per 107 cells per second.

    Drug Sensitivity Assays. Drug sensitivity was determined using the dye resazurin (Alamar blue) exactly as described previously (Wallace et al., 2002) in a protocol adapted from Räz et al. (1997). In brief, drugs were serially diluted in 100 µl of complete HMI-9 media across a 96-well microtiter plate. Unless limited by solubility, the top drug concentration used was 1 mM. Cultures of bloodstream-form trypanosomes were grown to a maximum density of 2 x 106 cells/ml and diluted to 2 x 105 cells/ml with complete HMI-9 medium, of which 100 µl was added to all wells. Plates were then incubated for 48 h at 37°C in a 5% CO2 atmosphere, before the addition of 20 µl of 5 mM resazurin (Sigma, St. Louis, MO) solution in PBS, pH 7.4. Plates were incubated for an additional 24 h at 37°C, before fluorescence was measured using a LS 55 luminescence spectrometer (ex = 530 nm, em = 590 nm; PerkinElmer Life and Analytical Sciences, Boston, MA).

    Fluorescence Microscopy. T. brucei were pelleted (600g, 10 min at room temperature) before being resuspended in fresh HMI-9 media containing 10 µM concentrations of stilbamidine, 4',6-diamidino-2-phenylindole dihydrochloride (DAPI), DB75, or Hoechst 33342 solution at room temperature and assessed by fluorescence microscopy. Glass slides of the culture were prepared and examined using differential interference contrast (DIC) and fluorescence microscopy (ex = 365 nm; em = 445 nm) on an Axioplan 2 imaging microscope (Carl Zeiss GmbH, Jena, Germany) using Volocity v. 3.7 software (Improvision, Coventry, UK). Where necessary, parasites were fixed by incubating in PBS containing 2.5% glutaraldehyde for 20 min. Cells were then washed in 0.05 M glycine in PBS before being mounted on slides.

    Lysis Assays. The lysis assays were performed essentially as described by Fairlamb et al. (1992), using bloodstream trypanosomes of tbat1-/- and KO-B48 grown in vitro. They were washed and resuspended in fresh HMI-9 medium with 10% fetal calf serum at 2 x 107 cells/ml, which was transferred to 1-ml cuvettes. Absorption was monitored, at 750 nm, at 30-s intervals. Melarsen oxide or phenylarsine oxide were added after 15 min to allow the recording of a short baseline. Up to 16 cultures were monitored simultaneously, using two HP8453 spectrophotometers (Hewlett-Packard), in the presence or absence of low concentrations of pentamidine, which by themselves did not affect cell viability or motility over the course of the experiment.

    Preparation of Plasma Membrane Protein-Enriched Fractions. tbat1-/- and KO-B48 plasma membrane-enriched samples were generated by a modification of the procedure described by Voorheis et al. (1979). In brief, bloodstream-form trypanosomes were cultured in vivo in adult female Wistar rats infected by i.p. injection. Blood was collected at peak parasitemia under terminal anesthesia, and parasites were isolated as for transport assays. Cells were then osmotically stressed by addition of water (at 4°C), and swelling was monitored by phase-contrast microscopy until a spherical morphology had been achieved. Cells were then homogenized in an AO Cell Disruptor (Stansted Fluid Power, Stansted, UK), in the presence of protease inhibitors. The homogenate was then returned to a normal osmotic potential through the addition of 3 M KCl to a final concentration of 140 µM, before pelleting the cells. Cells were then treated with 240 units of DNase in TES buffer (20 mM TES, 150 mM KCl, 5 mM MgCl2, and 1 mM 2-mercaptoethanol, pH 7.4), for 5 min at 20°C. The reaction was terminated by the addition of 5 volumes of TES buffer (20 mM TES, 150 mM KCl, 1 mM EDTA, and 1 mM 2-mercaptoethanol, pH 7.4). Cells were pelleted and then re-suspended in 40% sucrose before being layered on a linear 40 to 60% sucrose gradient (in TES buffer). Samples were then centrifuged for 3 h at 70,000g on a SW28 rotor (Beckman Coulter, Fullerton, CA). The most prominent dense white band, corresponding to the plasma membrane fraction, was isolated and washed twice in TES buffer to remove sucrose, before being aliquoted and stored in TES buffer at -80°C. All procedures were performed at 4°C unless otherwise stated.

    Western Blotting. Samples for Western blotting were plasma membrane preparations (described under Preparation of Plasma Membrane Protein-Enriched Fractions) or whole-cell protein extracts prepared from 2 x 107 cells, washed in PBS, and flash-frozen in dry ice/ethanol. Samples solubilized in standard Laemmli buffer (60°C for 10 min) were loaded onto a 10% SDS polyacrylamide gel and run until the bromphenol blue dye front reached the end of the gel. Proteins were then transferred onto a nitrocellulose membrane (Hybond ECL; GE Healthcare, Little Chalfont, Buckinghamshire, UK) at 4°C in MeOH Tris-glycine buffer. Blots were incubated in blocking solution (TBS-Tween 20 containing 5% milk powder) for 1 h at room temperature (RT). Primary antibodies raised to MRPA, kindly provided by Christine Clayton, University of Heidelberg, were diluted 1:500 in blocking solution (TBS-Tween 20 containing 5% milk powder) and incubated with the blot for 1.5 h at RT. Unbound/excess antibodies were removed by washing in TBS-Tween 20 (2 x 10 min) and then TBS (10 min). Secondary peroxidase-conjugated anti-mouse immunoglobulin antibodies (Dako Denmark A/S, Glostrup, Denmark) were then incubated with the blot (diluted 1:1000) in blocking solution at RT for 1 h. Unbound secondary antibodies were removed by washing (as with primary antibodies). Bound antibodies were detected using the ECL Plus western blotting detection System (GE Healthcare) according to the manufacturer's instructions. For normalization, the blot was stripped and reprobed using a polyclonal antiserum against paraflagellar rod protein (PFR; diluted 1:1000) as described previously (Schlaeppi et al., 1989) and a secondary peroxidase-conjugated anti-rat immunoglobulin antibody (diluted 1:10,000) (Dako Denmark A/S).

    Fig. 1. Induction of pentamidine resistance in T. brucei brucei. A, development of resistance over time in three independent clones. B and C, growth of KO-B48 line in the presence () or absence () of 80 nM pentamidine in the growth medium. Frame B, shortly after passage to 80 nM pentamidine; frame C, after 2 month in 80 nM pentamidine.

    Infectivity of Pentamidine-Adapted T. brucei brucei Lines in Mice. Groups of three to five ICR mice (Harlan UK Ltd., Bicester, Oxon, UK) were infected with 104 trypanosomes in 200 µl of full HMI-9/fetal calf serum culture medium by i.p. injection. In some cases, the mice had been immunosuppressed by treatment with cyclophosphamide (200 mg/kg cyclophosphamide in water, injected i.p.) 24 h before infection. Parasitemia was estimated daily by the rapid "matching" method (Herbert and Lumsden, 1976) from examinations of wet blood films on microscope slides, collected by tail prick, using a phase-contrast microscope. Mice reaching a parasitemia of antilog 8.4 (2.5 x 108 cells/ml blood) or over were euthanized by inhalation of a rising concentration of CO2.

    Induction of High-Level Pentamidine Resistance in T. brucei brucei. To maximize the likelihood of the successful generation of drug-resistant lines, we applied selection pressure to four separate cultures from each of the two parental strains, s427 (WT) and the isogenic clone tbat1-/-, the latter of which has been derived from the former by deletion of both copies of the TbAT1 gene (Matovu et al., 2003). From these 8 cultures initially established, three (WT-D, KO-B, and KO-D) went on to develop a stable drug resistance phenotype after several months of selection in increasing pentamidine concentrations. Two clones were derived from each of these lines: one that tolerated intermediate levels of pentamidine (clones WT-D3, KO-B6, and KO-D6) and one that tolerated high levels of pentamidine (clones WT-D24, KO-B48, and KO-D48), compared with the parental strains (Fig. 1A). The strains displaying the highest levels of resistance were able to survive in pentamidine concentrations 80-fold higher than those tolerated by their parental strain. It was also observed that resistance acquisition was nonlinear over time and seemed to correlate best to an exponential model, with correlation coefficients between 0.87 and 0.93 (plots not shown). The wild-type strain, in particular, took many passages to acquire any pentamidine resistance but subsequently adapted to very significant levels of resistance in two discrete steps.

    During each round of selection, it was observed that the initial acquisition of resistance in the presence of drug was associated with a reduced growth phenotype (Fig. 1B), in terms of both doubling time and maximum cell density. For all the lines eventually selected, this was reversed to a parental growth phenotype by maintaining the same selection pressure for an additional period of time (Fig. 1C). Once the resistance phenotype was well established, removal of pentamidine from the media had no effect on growth, and the resistance phenotype was stable for at least 3 months in the absence of drug pressure.

    Cross-Resistance Profile of KO-B48 and KO-D48. We have previously reported the cross-resistance phenotype of the tbat1-/- strain (Matovu et al., 2003), which displayed high levels of resistance to diminazene but only minor loss of sensitivity to pentamidine and the melaminophenyl arsenical drugs melarsoprol, melarsen oxide, and melarsamine hydrochloride. Using the same protocol based on the reduction of the dye Alamar blue (resazurin), we have repeated these experiments with WT, tbat1-/-, KO-B48, and KO-D48 in parallel. The results are presented as a series of bar graphs in Fig. 2. The phenotypes of KO-B48 and KO-D48 were very similar. Compared with the WT strain, a large increase in pentamidine resistance was observed, reaching an average 130- and 82-fold resistance in KO-B48 and KO-D48, respectively (n = 8; Fig. 3). Resistance to melarsen oxide was also markedly increased in KO-B48 and KO-D48 (15.4- and 10.7-fold, respectively, relative to WT; Fig. 2B). Sensitivity to propamidine and stilbamidine, already reduced in the KO strain, was modestly decreased further in KO-B48 and KO-D48 (Fig. 2, C and D), whereas resistance to diminazene aceturate was not further increased in the pentamidine resistant lines (Fig. 2E). Sensitivity to phenylarsine oxide, which freely diffuses across membranes, was identical in all the lines (Fig. 2E), showing that the resistance phenotype was most likely associated with changes in drug uptake. A table with exact sensitivities of all four trypanosome lines to all six drugs is included as on-line only Supplementary Data.

    Fig. 2. Drug sensitivity profile of four T. brucei brucei clones. A, pentamidine. B, melarsen oxide. C, propamidine. D, stilbamidine. E, diminazene aceturate. F, phenylarsine oxide (PAO). Error bars indicate S.E. All values are the average of between 3 and 11 determinations. A table with the exact values and number of replicates is available as on-line only supplementary material.

    Fig. 3. Sensitivity of four T. brucei brucei clones to pentamidine (A) and melarsen oxide (B). Lines used were WT (), KO, (), KO-B48 (), and KO-D48 (). The data shown is a representative experiment using the Alamar blue method as described under Materials and Methods section. IC50 values were calculated by nonlinear regression. Fluorescence is given in arbitrary units on a scale of 0 to 1000. The lowest concentration data point is the "no drug" control.

    Pentamidine Transport in Pentamidine-Resistant Trypanosome Lines. Transport of 0.5 µM[3H]pentamidine was drastically reduced in both KO-B48 and KO-D48, compared with the parental tbat1-/- line (Fig. 4A, B), by 74 and 68%, respectively. To exclude the possibility that culture conditions had somehow played a role in the reduced uptake rates, the experiment was repeated with tbat1-/- and KO-B48 cells grown in Wistar rats (Fig. 4C). The result clearly demonstrates that pentamidine transport in the adapted lines is severely impaired yet remains saturable (Figs. 4C and 5). We also confirmed that transport in KO-B48 was not generally impaired, using [3H]2-deoxyglucose. Uptake of [3H]2-deoxyglucose by KO and KO-B48 cells was determined in three independent experiments, each performed in triplicate, and found to be linear over 30 min, completely saturated by 10 mM 2-deoxyglucose, and not significantly different between the two trypanosome lines (Supplementary Data Fig. 1).

    Fig. 4. Transport of 0.5 µM[3H]pentamidine in resistant trypanosome lines. A, uptake of pentamidine by KO-B48 () or the parental tbat1-/- strain () grown in culture in the absence of pentamidine pressure and the two strains were assayed simultaneously. Lines were calculated by linear regression. B48, r2 = 0.89, slope = 0.027 ± 0.005; tbat1-/-, r2 = 0.99, slope = 0.10 ± 0.006. B, uptake of pentamidine by KO-D48 () or the parental tbat1-/- strain () grown in culture in the absence of pentamidine pressure and the two strains were assayed simultaneously. Lines were calculated by linear regression. D48, r2 = 0.97, slope = 0.038 ± 0.005; tbat1-/-, r2 = 0.99, slope = 0.17 ± 0.01. C, uptake of [3H]pentamidine by KO-B48 (, ) or the parental tbat1-/- strain (, ) grown in Wistar rats, in the presence (open symbols) or absence (filled symbols) of 1 mM nonlabeled pentamidine. Lines were calculated by linear regression. Values in the absence of pentamidine were as follows: B48, r2 = 0.97, slope = 0.0032 ± 0.0001; tbat-/-, r2 = 0.94, slope = 0.021 ± 0.002. Pentamidine uptake is expressed as picomoles per 107 cells. Symbols represent average of triplicate determinations; error bars are S.E., when not shown fall within the symbol.

    Fig. 5. Pentamidine uptake in Trypanosoma brucei brucei clone KO-B48 is mediated only by a low-affinity transporter. A, transport of 0.015 µM [3H]pentamidine in KO-B48 over 2.5 min was assayed in the presence or absence of increasing concentrations of unlabeled pentamidine. The data were fitted to a sigmoid curve using nonlinear regression. B, uptake of 0.04 µM[3H]pentamidine over 60 s in LS bloodstream forms of s427 WT was assessed in the presence of a constant concentration of 1 mM adenosine and a variable concentration of unlabeled pentamidine. The data were fitted to a "two-site competition" equation in the GraphPad Prism 4.0 software package. IC50 values were 0.13 and 85 µM for the high- and low-affinity components, respectively. C, conversion of the inhibition data in frame A to a Michaelis-Menten plot. All data shown are the average of triplicate determinations; error bars are S.E. Pentamidine uptake is expressed as picomoles per 107 cells per second.

    Pentamidine transport in the tbat1-/- strain is mediated by two transporters, HAPT1 and LAPT1 (Matovu et al., 2003). To determine whether one or both of these transporters were affected in the highly resistant line KO-B48, a series of transport assays was performed at 15 nM [3H]pentamidine. This very low concentration of radiolabel is necessary to avoid saturating HAPT1 and to obtain a biphasic inhibition curve showing both the high-affinity (but low-capacity) HAPT1 activity and the low-affinity (but high-capacity) LAPT1 activity in the WT s427 and tbat1-/- strains (De Koning, 2001b; Matovu et al., 2003). The presence of a high-affinity pentamidine transport activity could not be confirmed in KO-B48: it was either absent altogether or its transport capacity was very significantly reduced (Fig. 5A), although pentamidine transport was clearly biphasic in the control WT strain (Fig. 5B). In contrast, the low-affinity transporter LAPT1 seemed completely unchanged compared with parental strains (Fig. 5, A and C): Km and Vmax values were identical to those previously reported for the parental line s427 (Table 1).

    TABLE 1 Kinetic parameters of pentamidine transporters in various cloned trypanosome lines

    Arsenical-Induced Lysis in tbat1-/- Is Mediated by HAPT1 and Absent in KO-B48. Lysis of trypanosomes, induced by arsenical drugs, can be monitored spectroscopically at 750 nm (Fairlamb et al., 1992) and was used to demonstrate that melaminophenyl arsenicals enter T. brucei brucei principally through P2 (Carter and Fairlamb, 1993). We have previously used this technique to show that in tbat1-/- cells, a secondary, slower phase of melarsen oxide-induced lysis can be discerned and displays the pharmacological profile of HAPT1 (Matovu et al., 2003). The results depicted in Fig. 6A confirm this observation. Although melaminophenyl arsenicals act more slowly on tbat1-/- than on WT cells (Matovu et al., 2003), 10 µM melarsen oxide induced cell lysis in tbat1-/- cells in approximately 50 min (trace a), but coadministration of as little as 1 µM pentamidine with 10 µM melarsen oxide substantially delayed cell lysis (trace b). In contrast, the same concentration of pentamidine had no influence on lysis induced by phenylarsine oxide (traces c and d), which rapidly diffuses across membranes (Carter and Fairlamb, 1993).

    Fig. 6. Lysis of trypanosomes induced by 10 µM melarsen oxide. A, strain tbat1-/-. B, strain KO-B48. Melarsen oxide (10 µM) was added after 15 min of recording, as 50 µl [200 µM] in full HMI-9 medium added to 1 x 107 (A) or 1.5 x 107 T. brucei brucei in 1 ml of full HMI-9 medium being monitored at 750 nm. Conditions from t = 0 min: a, 10 µM melarsen oxide; b, 10 µM melarsen oxide plus 1 µM pentamidine; c, 0.5 µM phenylarsine oxide; d, 0.5 µM phenylarsine oxide plus 1 µM pentamidine; e, control, no drug. Dotted lines indicate the incubations in the presence of 1 µM pentamidine.

    In KO-B48 cells, melarsen oxide-induced lysis is already much delayed compared with tbat1-/- cells (trace a), and 1 µM pentamidine has no further effect (trace b), demonstrating the absence of HAPT1 activity. Again, coincubation with 1 µM pentamidine had no effect on lysis induced by phenylarsine oxide (traces c and d), and the timing of phenylarsine-induced lysis was identical in both strains.

    Assessment of Pentamidine Transporters Using Fluorescent Microscopy. The rate of entry of fluorescent diamidines, monitored by fluorescence-activated cell sorting or fluorescence microscopy, can be used as a probe to investigate changes in membrane permeability and cross-resistance patterns (Frommel and Balber, 1987; Stewart et al., 2005). Like Frommel and Balber (1987), we used 4',6-diamidino-2-phenylindole dihydrochloride as a fluorescent substitute for pentamidine. This was possible given the fact that DAPI displays considerable affinity for all three pentamidine transporters. Ki values are 0.67 ± 0.12 µM (TbAT1/P2, n = 3), 26 ± 6 µM (HAPT1, n = 3), and 20 ± 6 µM (LAPT1, n = 5) (data not shown). The highest affinity was for TbAT1/P2; nonetheless, this transporter did not primarily mediate DAPI transport. Figure 7 shows that the rate of development of fluorescence was not clearly different in live long-slender WT s427 or tbat1-/- cells. By 5 min, fluorescence was clearly observed, and by 10 min, staining of both nucleus and kinetoplast was very intensive. In contrast, KO-B48 cells showed only faint fluorescence in both organelles after 20 min. Even after 60 min, fluorescence was much less than that observed in the other cell lines at 10 min (Fig. 7). Care was taken to exclude any dead cells from the observations, as they accumulated DAPI very rapidly, presumably as a result of loss of membrane integrity.

    Fig. 7. Assessment of DAPI uptake using fluorescent microscopy over time. LS bloodstream forms of WT s427, tbat1-/- and KO-B48 were incubated with 10 µM DAPI and fluorescence was observed under an Axioplan 2 imaging microscope (ex = 365 nm, em = 445 nm) at 1000x magnification.

    It thus seems that the rate of DAPI uptake is much reduced in KO-B48 cells, relative to the parental line tbat1-/-. To assess whether this was caused by the loss of HAPT1 or LAPT1, the development of fluorescence was again monitored in live KO-B48 cells incubated with DAPI alone or in the presence of either 10 µM pentamidine (saturates HAPT1) or 1 mM pentamidine (saturates both transporters). The results in Fig. 8A show accumulation in live cells at 25, 45, and 60 min of incubation with the fluorophore. It is clear that the lower concentration of pentamidine does not delay the rate of DAPI accumulation compared with the no-drug control, whereas 1 mM pentamidine practically abolishes DAPI fluorescence over 60 min. The P-glycoprotein inhibitor verapamil (50 µM) did not affect the accumulation rate of DAPI (Fig. 8A). Using live, motile trypanosomes does not allow the overlay of DIC and fluorescent images and causes imperfect focus on the fluorescence micrographs. At the termination of the experiment, at 60 min, cells were therefore fixed with glutaraldehyde. The higher quality DIC, fluorescence, and overlay images shown in Fig. 8B confirm the conclusions of the timed/real time experiment depicted in Fig. 8A.

    Fig. 8. DAPI fluorescence acquisition in live KO-B48 cells incubated in the absence or presence of a low (10 µM) or high (1 mM) concentration of pentamidine, or 50 µm verapamil over time (A). Separate images (DIC, DAPI, and combined overlay) from glutaraldehyde-fixed parasites after 60-min incubation with DAPI in the presence or absence of pentamidine (B). DAPI concentration was 10 µM. Magnification was 1000x. Comb, combined overlay.

    The Drug Efflux Transporter TbMRPA Is Not Overexpressed in KO B-48. To verify whether the cross-resistance phenotype of KO B-48 can be partly explained through the elevated expression of TbMRPA, an ABC transporter of the multidrug resistance (mdr) family, plasma membrane-enriched extracts of tbat1-/- and KO B-48 were run on one-dimensional SDS polyacrylamide gels and transferred to nitrocellulose for Western blotting with anti-TbMRPA antiserum. Protein preparations from tetracycline-induced and noninduced NY-mrpa cells and parental NY trypanosomes were analyzed in parallel as control cells. MRPA was clearly present in NY-mrpa+ cells but could not be detected in any of the other lines (Fig. 9A). In contrast, the presence of PFR could easily be demonstrated in each of the preparations (Fig. 9B).

    Fig. 9. TbMRPA expression in various Trypanosoma brucei brucei lines. Western blots with extracts of tbat1-/- (lane 1), KO-B48 (lane 2), NY-mrpa+ (lane 3), NY-mrpa(lane 4), and NY (lane 5), using anti-TbMRPA (A) or PFR antisera (B).

    Infectivity of the KO-B48 and KO-D48 Lines. During in vivo culturing it was observed that infectivity of both KO-B48 and KO-D48 lines was much reduced compared with WT and tbat1-/- lines. To assess this systematically, groups of five mice were infected with 104 T. brucei brucei organisms from tbat1-/- and each of the derived pentamidine resistant lines. In both KO-B6 and KO-B48 groups, all mice developed detectable parasitemia within 3 days, which, however, rapidly disappeared. Two mice of the KO-B48 group suffered 1 or 3 subsequent relapses, otherwise, no parasitaemia was detectable in thick blood smears taken daily. No parasitaemia was observed at all in the KO-D6 group, and only one mouse in the KO-D48 group developed a brief, low parasitaemia on day 5. In contrast, the tbat1-/- line appeared far more virulent. One group of mice was infected with tbat1-/- cells from a long-term culture. All mice rapidly developed substantial parasitaemia, and two mice had to be euthanized. In the last group, infected with the same number of tbat1-/- cells from stabilates kept in liquid nitrogen and only briefly brought back into culture, all mice developed massive parasitaemia and were euthanized (four on day 4, one on day 13). To investigate whether the lack of infectivity was innate to the adapted trypanosome lines or dependent on the immune system, groups of immunocompromised mice were infected. As shown in Fig. 10A, all mice infected with tbat1-/- cells developed similar parasitaemia and were euthanized on day 7. In the KO-B48 and KO-D48 groups (Fig. 10, B and C), all mice similarly established substantial parasitaemia; in all but one mouse in the KO-B48 group, however, these were transient and the mice apparently self-cured.

    Fig. 10. Parasitaemia in T. brucei brucei infected mice. Progression of T. brucei brucei infections in immunocompromised mice after intraperitoneal inoculation with equal numbers of tbat1-/- (A), KO-B48 (B), and KO-D48 (C). Animals reaching a parasite burden of 108 or more were euthanized, indicated with a double bar. Each group consisted of three mice, represented by symbols , , and . PI, postinfection.

    An Arsenical-Resistant T. brucei gambiense Clone Has Lost TbAT1 and HAPT1. To assess whether loss of HAPT1 activity is peculiar to selection with pentamidine, we also assessed [3H]pentamidine transport in a T. brucei gambiense type 2 clone, 386Mr, adapted for high levels of melarsamine hydrochloride resistance in vivo (Scott et al., 1996). The [3H]pentamidine transport profile of the parental line STIB 386Ms, conformed to the same three-transporter model as the earlier characterized T. brucei brucei s427 (De Koning, 2001b; Bray et al., 2003). Using fluorescence microscopy similar to the experiments shown here, it has previously been shown that 386Mr accumulates the diamidine DB99 much more slowly than the parental line (Stewart et al., 2005).

    Figure 11A shows that uptake of 0.015 µM[3H]pentamidine was inhibited partly by adenosine, with a Ki value of 1.8 µM, consistent with inhibition of TbAT1/P2. A second component, assessed in the presence of 1 mM adenosine, was revealed by a dose-dependent inhibition with propamidine, which inhibits HAPT1 but not LAPT1 (De Koning, 2001b), with a Ki value of 9.0 ± 3.0 µM(n = 3). The third transport activity was evident as inhibited by high concentrations of unlabeled pentamidine but not by propamidine or adenosine, consistent with LAPT1 activity. In contrast to 386Ms, transport of [3H]pentamidine in 386Mr was not sensitive to either adenosine or propamidine (Fig. 11B), showing the absence of TbAT1 and HAPT1 activity in these cells.

    Fig. 11. Transport of 0.015 µM[3H]pentamidine in T. brucei gambiense 386Ms (A) and 386Mr. Uptake was measured over 60 s in the presence or absence of adenosine (), propamidine (), or unlabeled pentamidine (). Incubations with propamidine or pentamidine were performed in the presence of 1 mM adenosine to saturate the TbAT1/P2 transporter. Data shown are the average of triplicate determinations; error bars are S.E. Pentamidine uptake is expressed as picomoles per 107 cells per second.

    The Km and Vmax values of HAPT1 and LAPT1 activities in the T. brucei gambiense lines are listed in Table 1 and are very similar to those determined in WT T. brucei brucei. Table 1 also shows that the Vmax of LAPT is not changed in the resistant T. brucei gambiense line, relative to its parental line.

    In principle, pentamidine resistance in African trypanosomes could be associated with changes in the intracellular drug target, with reduced uptake of the drug or with active extrusion from the cell by an ABC-type efflux pump.

    It has been shown that, in wild-type T. brucei brucei, pentamidine uptake is very rapid and efficient, amounting to a cytosolic concentration corresponding to at least 1 mM, if the drug were to remain unbound (Damper and Patton, 1976). Such an intracellular accumulation of the drug is liable to interfere with multiple vital processes and it has long been hypothesized that resistance would most likely be associated with a reduction in cellular levels (Wang, 1995). Indeed, different authors (Wang, 1995) have demonstrated various effects of pentamidine on cellular processes. Pentamidine resistance in T. brucei brucei based on acquired mutations in any one target, while impossible to rule out, would thus seem unlikely.

    Another potential route to drug resistance is the expression of ABC transporters capable of actively removing the toxic compound from the cell. Strong evidence couples this mechanism to drug resistance in some protozoa, including Plasmodium and Leishmania spp. and Entamoeba histolytica (Légaré et al., 2001; Lopez-Camarillo et al., 2003). In T. brucei, three ABC transporter genes have been identified (Mäser and Kaminsky, 1998). However, in studies with the P-glycoprotein inhibitor verapamil, no evidence could be found for the involvement of such transporters in multidrug resistance in T. brucei brucei, either in vitro or in vivo (Kaminsky and Zweygarth, 1991). Experimental overexpression of the T. brucei brucei ABC transporter TbMRPA led to substantial melarsoprol resistance in vitro (Shahi et al., 2002) but not in vivo, and TbMRPA overexpression was not observed in melarsoprol-resistant clinical isolates from a number of patients with sleeping sickness (Alibu et al., 2006).

    Thus, although resistance based on target modifications or active efflux cannot be excluded, the available information is consistent with changes to drug entry being the cause of arsenical and diamidine resistance in African trypanosomes. Our findings, using pentamidine-adapted laboratory strains, are strongly in agreement with this hypothesis. We identify HAPT1 as potentially a key drug resistance determinant and for the first time provide a biochemical model for high-level arsenical-diamidine cross-resistance in African trypanosomes.

    High-Level Pentamidine Resistance Is Associated with Loss of HAPT1 but Not of LAPT1 Activity. Several independent lines of evidence suggested that the pentamidine-adapted lines KO-B48 and KO-D48 had lost HAPT1 rather than LAPT1 activity. Because the adaptation started with the tbat1-/- clonal line, P2 transport activity was also not present. We have shown previously that propamidine is an inhibitor of high-affinity pentamidine transport in T. brucei but not of the low-affinity transport component (De Koning, 2001b), and the increase in propamidine resistance is certainly consistent with loss of HAPT1 activity. Furthermore, there was no increased resistance to diminazene aceturate, which is transported only by TbAT1/P2 (De Koning et al., 2004), or to phenylarsine oxide, which diffuses across membranes.

    The resistance profiles and [3H]pentamidine transport rates of the two adapted lines were highly similar. These experiments measured initial rates of pentamidine uptake rather than accumulation, and the results can only be explained in terms of deficient uptake rather than active extrusion or intracellular sequestration. Unlike T. brucei brucei s427 and tbat1-/- (De Koning, 2001b; Matovu et al., 2003), transport of 15 nM [3H]pentamidine in KO-B48 was not inhibited by submicromolar concentrations of unlabeled pentamidine, saturated only by very high levels of the substrate, and Km and Vmax values were identical to those reported earlier for LAPT1 (De Koning, 2001b).

    In tbat1-/-, lysis induced by melarsen oxide was very considerably delayed, relative to T. brucei brucei s427, by coadministration of as little as 1 µM pentamidine-sufficient to saturate HAPT1 but not LAPT1. Pentamidine was apparently competing with the arsenical drug for transporter-mediated import, because 1 µM of pentamidine had no effect on the rapid lysis induced by phenylarsine oxide. These experiments clearly demonstrate the uptake of melarsen oxide through HAPT1. The same process was assessed by monitoring DAPI fluorescence as a marker for diamidine accumulation. Scant difference was observed between the WT and tbat1-/- lines, but the development of fluorescence was substantially delayed in KO-B48 cells (Fig. 7), indicating a loss of diamidine transport unrelated to TbAT1/P2. The remaining DAPI transport activity was saturated by 1 mM but not by 10 µM pentamidine, consistent with uptake through LAPT1 rather than HAPT1.

    The Role of HAPT1 in Accumulation of Melaminophenyl Arsenicals. Since the seminal observations of Carter and Fairlamb (1993) that a T. brucei brucei line adapted to high levels of resistance to melaminophenyl arsenicals had lost activity of a transporter they named P2, much evidence has accumulated linking TbAT1/P2 to arsenical resistance (Carter et al., 1999; Delespaux and De Koning, 2006). Loss of P2 activity alone was not sufficient to establish substantial arsenical resistance as the tbat1-/- line was less than 3-fold resistant to melarsen oxide and melarsoprol (Matovu et al., 2003). We show here that lysis of trypanosomes induced by melaminophenyl arsenicals, but not by phenylarsine oxide, was 1) sensitive to inhibition by 1 µM pentamidine and 2) much delayed in KO-B48 cells. The level of resistance to melarsen oxide reached 15-fold in KO-B48. We conclude that high levels of arsenical resistance can be induced by selection with pentamidine and can be achieved by the sequential loss of TbAT1 and HAPT1. The example with T. brucei gambiense 386Mr shows that selection with melaminophenyl arsenicals can likewise lead to loss of the same two transporters, thus explaining reported incidences of pentamidine/arsenical cross-resistance (Frommel and Balber, 1987; Kaminsky and Mäser, 2000). High levels of resistance could be far more easily induced when starting from a TbAT1-null background. This is potentially significant given the increasing levels of resistance to melarsoprol and diminazene aceturate in the field, believed to be at least partially linked to loss of TbAT1/P2 activity in the resistant strains (Kaminsky and Mäser, 2000; De Koning et al., 2004; Delespaux and De Koning, 2006).

    It must be acknowledged that our findings have been generated under laboratory conditions and that any clinical link between loss of HAPT and diamidine or melarsoprol treatment failure remains theoretical. However, the previous explanation for the observed treatment failures (loss of TbAT1/P2 only) proved unsatisfactory (Matovu et al., 2003), and we here propose an improved model that can now be tested against the situation in the field. Efforts to identify the genes encoding HAPT and LAPT are ongoing and would greatly assist the evaluation of this model against clinical isolates.

    It is possible that additional mechanisms of resistance to melaminophenyl arsenicals may exist, because cross-resistance is not always observed (e.g., Fairlamb et al., 1992). However, conclusions based on a review of the literature are complicated by differences in technique (e.g., in vitro or in vivo assessment of resistance), variations in drugs tested, and other confounding factors.

    The Role of Drug Efflux: ABC Transporters. It has been demonstrated that overexpression of the T. brucei brucei ABC transporter MRPA resulted in a 10-fold resistance to melarsoprol in vitro (Shahi et al., 2002), an effect that was additive with the effect of TbaT1 deletion (Lüscher et al., 2006). However, we found no detectable levels of TbMRPA in the two pentamidine-adapted lines. In addition, we found that the P-glycoprotein inhibitor verapamil had no effect on DAPI accumulation, and thus we have been unable to find evidence that the increased resistance phenotype is the result of increased activity of P-glycoprotein or mdr-type ABC-transporters.

    Is Pentamidine Resistance Associated with Reduced Virulence? Pentamidine is still the first-line drug for early-stage gambiense sleeping sickness. Treatment failures are rare but stable over at least three decades (Pépin and Milord, 1994). In contrast, pentamidine resistance seems to emerge easily in Leishmania species (Papadopoulou et al., 1998), though pentamidine usage against leishmaniasis has been very much less widespread than against African trypanosomiasis. The difference can be explained in part by the involvement of an mdr-type ABC transporter in pentamidine efflux from Leishmania (Coelho et al., 2003) and the fact that pentamidine uptake in Leishmania is apparently mediated by a single transporter (Basselin et al., 2002; Bray et al., 2003). The presence of three pentamidine transporters in T. brucei brucei has been argued to be responsible for the lack of clinical resistance to pentamidine (Bray et al., 2003). However, it has been demonstrated that trypanosomes with defective tbat1 genes can be isolated from sleeping sickness patients (Matovu et al., 2001), and we show here that the further loss of just HAPT1 leads to very significant levels of pentamidine resistance. The presence of multiple accumulation routes alone may thus not be sufficient to prevent the occurrence of resistance. One explanation would be loss of viability or virulence in the resistant parasites. Berger et al. (1995) reported that pentamidine adapted T. brucei brucei clone PR32.6 was far less virulent than the parental strain and excluded increased susceptibility to the host's immune system or changes attributable to prolonged culturing as factors. The phenotype of the KO-B48 and KO-D48 lines seems identical to that of PR32.6. These lines were less infective in mice and rats than the parental line, which had been cultured at least equally long, and immunosuppression of the animals did not lead to substantially higher parasitaemia. There is thus a distinct possibility that high-level pentamidine resistance is not viable in the field, and self-limiting.

    Acknowledgements

    We are grateful to Professor Mike Turner for the use of T. brucei gambiense strains 386Ms and 386Mr and to Professor Christine Clayton for the gift of anti-TbMRPA antiserum. We are particularly grateful to Professor Paul Voorheis (University of Dublin) for expert advice and assistance on the preparation of plasma membrane protein-enriched fractions for Western blotting.

    ABBREVIATIONS: LAPT1, low-affinity pentamidine transporter; HAPT1, high-affinity pentamidine transporter; ABC, ATP-binding cassette transporter; TbAT1, Trypanosoma brucei adenosine transporter 1; MRPA, multidrug resistance protein A; TbMRPA, Trypanosoma brucei multidrug resistance protein A; DAPI, 4',6-diamidino-2-phenylindole dihydrochloride; DIC, differential interference contrast; TES, N-tris(hydroxymethyl)-methyl-2-aminoethanesulfonic acid; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; RT, room temperature; PFR, paraflagellar rod protein; WT, wild-type.

    The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

【参考文献】
  Alibu VP, Richter C, Voncken F, Marti G, Shahi S, Renggli CK, Seebeck T, Brun R, and Clayton C (2006) The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Mol Biochem Parasitol 146: 38-44.[CrossRef][Medline]

Basselin M, Denise H, Coombs GH, and Barrett MP (2002) Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother 46: 3731-3738.[Abstract/Free Full Text]

Berger BJ, Carter NS, and Fairlamb AH (1995) Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Mol Biochem Parasitol 69: 289-298.[CrossRef][Medline]

Bray PG, Barrett MP, Ward SA, and De Koning HP (2003) Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 19: 232-239.[CrossRef][Medline]

Carter NS, Barrett MP, and De Koning HP (1999) A drug resistance determinant in Trypanosoma brucei. Trends Microbiol 7: 469-471.[CrossRef][Medline]

Carter NS and Fairlamb AH (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature (Lond) 361: 173-176.[CrossRef][Medline]

Coelho AC, Beverley SM, and Cotrim PC (2003) Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol 130: 83-90.[CrossRef][Medline]

Damper D and Patton CL (1976) Pentamidine transport and sensitivity in brucei-group trypanosomes. J Protozool 23: 349-356.[Medline]

De Koning HP (2001a) Transporters in African trypanosomes: role in drug action and resistance. Int J Parasitol 31: 512-522.[Medline]

De Koning HP (2001b) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol Pharmacol 59: 586-592.[Abstract/Free Full Text]

De Koning HP, Anderson LF, Stewart M, Burchmore RJ, Wallace LJ, and Barrett MP (2004) The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in African trypanosomes. Antimicrob Agents Chemother 48: 1515-1519.[Abstract/Free Full Text]

De Koning HP and Jarvis SM (1997) Purine nucleobase transport in bloodstream forms of Trypanosoma brucei is mediated by two novel transporters. Mol Biochem Parasitol 89: 245-258.[CrossRef][Medline]

De Koning HP and Jarvis SM (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Trop 80: 245-250.[CrossRef][Medline]

Delespaux V and De Koning HP (2007) Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat, in press.

Fairlamb AH, Carter NS, Cunningham M, and Smith K (1992) Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol 53: 213-222.[CrossRef][Medline]

Frommel TO and Balber AE (1987) Flow cytofluorimetric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T. b. rhodesiense. Mol Biochem Parasitol 26: 183-191.[CrossRef][Medline]

Fulton JD and Grant PT (1955) The preparation of a strain of Trypanosoma rhodesiense resistant to stilbamidine and some observations on its nature. Exp Parasitol 4: 377-386.[CrossRef][Medline]

Herbert WJ and Lumsden WH (1976) Trypanosoma brucei: a rapid "matching" method for estimating the host's parasitemia. Exp Parasitol 40: 427-431.[CrossRef][Medline]

Hirumi H and Hirumi K (1989) Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cells. J Parasitol 75: 985-989.[CrossRef][Medline]

Jannin J and Cattand P (2004) Treatment and control of human African trypanosomiasis. Curr Opin Infect Dis 17: 565-571.[CrossRef][Medline]

Kaminsky R and M?ser P (2000) Drug resistance in African trypanosomes. Curr Opin Anti-infect Investig Drugs 2: 76-82.

Kaminsky R and Zweygarth E (1991) The effect of verapamil alone and in combination with trypanocides on multidrug-resistant Trypanosoma brucei brucei. Acta Trop 49: 215-225.[CrossRef][Medline]

Légaré D, Cayer S, Singh AK, Richard D, Papadopoulou B, and Ouellette M (2001) ABC proteins of Leishmania. J Bioenerg Biomembr 33: 469-474.[CrossRef][Medline]

Lopez-Camarillo C, Luna-Arias JP, Marchat LA, and Orozco E (2003) EhPgp5 mRNA stability is a regulatory event in the Entamoeba histolytica multidrug resistance phenotype. J Biol Chem 278: 11273-11280.[Abstract/Free Full Text]

Lüscher A, Nerima B, and M?ser P (2006) Combined contribution of TbAT1 and TbMRPA to drug resistance in Trypanosoma brucei. Mol Biochem Parasitol 150: 364-366.[CrossRef][Medline]

M?ser P and Kaminsky R (1998) Identification of three ABC transporter genes in Trypanosoma brucei spp. Parasitol Res 84: 106-111.[CrossRef][Medline]

M?ser P, Sutterlin C, Kralli A, and Kaminsky R (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science (Wash DC) 285: 242-244.[Abstract/Free Full Text]

Matovu E, Geiser F, Schneider V, M?ser P, Enyaru JC, Kaminsky R, Gallati S, and Seebeck T (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol 117: 73-81.[CrossRef][Medline]

Matovu E, Stewart ML, Geiser F, Brun R, M?ser P, Wallace LJ, Burchmore RJ, Enyaru JC, Barrett MP, Kaminsky R, et al. (2003) Mechanisms of Arsenical and Diamidine Uptake and Resistance in Trypanosoma brucei. Eukaryot Cell 2: 1003-1008.[Abstract/Free Full Text]

Papadopoulou B, Kundig C, Singh A, and Ouellette M (1998) Drug resistance in Leishmania: similarities and differences to other organisms. Drug Resist Updat 1: 266-278.[CrossRef][Medline]

Pépin J and Milord F (1994) The treatment of human African trypanosomiasis. Adv Parasitol 33: 1-47.[Medline]

R?z B, Iten M, Grether-Buhler Y, Kaminsky R, and Brun R (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop 68: 139-147.[CrossRef][Medline]

Schlaeppi K, Deflorin J, and Seebeck T (1989) The major component of the paraflagellar rod of Trypanosoma brucei is a helical protein that is encoded by two identical, tandemly linked genes. J Cell Biol 109: 1695-1709.[Abstract/Free Full Text]

Scott AG, Tait A, and Turner CM (1996) Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin. Acta Trop 60: 251-262.[CrossRef][Medline]

Shahi SK, Krauth-Siegel RL, and Clayton CE (2002) Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Mol Microbiol 43: 1129-1138.[CrossRef][Medline]

Stewart ML, Krishna S, Burchmore RJ, Brun R, De Koning HP, Boykin DW, Tidwell RR, Hall JE, and Barrett MP (2005) Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet 366: 486-487.[CrossRef][Medline]

Voorheis HP, Gale JS, Owen MJ, and Edwards W (1979) The isolation and partial characterization of the plasma membrane from Trypanosoma brucei. Biochem J 180: 11-24.[Medline]

Wallace LJ, Candlish D, and De Koning HP (2002) Different substrate recognition motifs of human and trypanosome nucleobase transporters. Selective uptake of purine antimetabolites. J Biol Chem 277: 26149-26156.[Abstract/Free Full Text]

Wang CC (1995) Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 35: 93-127.[CrossRef][Medline]

Williamson J (1970) Review of chemotherapeutic and chemoprophylactic agents, in The African Trypanosomiases (Mulligan HW ed) pp 125-221, Allen and Unwin, London.

Williamson J and Rollo IM (1959) Drug resistance in trypanosomes: cross-resistance analyses. Br J Pharmacol Chemother 14: 423-430.[Medline]

Wirtz E, Leal S, Ochatt C, and Cross GA (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89-101.[CrossRef][Medline]

Witola WH, Inoue N, Ohashi K, and Onuma M (2004) RNA-interference silencing of the adenosine transporter-1 gene in Trypanosoma evansi confers resistance to diminazene aceturate. Exp Parasitol 107: 47-57.[CrossRef][Medline]


作者单位:Institute of Biomedical and Life Sciences, Division of Infection and Immunity, University of Glasgow, Glasgow, UK (D.J.B., M.K.G., R.J.S.B., H.P.d.K.), and Institute of Cell Biology, University of Bern, Switzerland (B.N., P.M.)

日期:2009年8月25日 - 来自[2007年第69卷第4期]栏目

4 Weight Loss Products Recalled

July 17, 2009 -- Young You Corp. of Tarzana, Calif., is recalling four of its weight loss products because they contain an undeclared drug, sibutramine, according to the FDA.

The recalled Young You products are:

  • Slimbionic: 30 capsules per box
  • One Weight Loss Pill: 30 capsules per box
  • SlimDemand Capsules: 30 capsules per box
  • Botanical Weight Loss: 30 capsules per box

Those products were sold online and through Young You's Weight Loss and Rejuvenation Center in Tarzana, Calif.

Sibutramine is the active ingredient in Meridia, a prescription appetite suppressant for weight loss. But the FDA hasn't approved sibutramine for use in Young You's products, so the FDA says the safety and effectiveness of the recalled Young You products is "unknown."

In a news release, the FDA advises consumers that the recalled products "pose a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrythmias, or stroke.

Young You Corp. also issued its own news release, which is posted on the FDA's web site. That news release, dated July 15, states that the recall is voluntary and that "no illnesses or injuries have been reported to the company" about the products that are being recalled.

日期:2009年7月19日 - 来自[Health News]栏目

Caffeine May Fight Alzheimer‘s Memory Loss

July 6, 2009 -- Getting your daily caffeine hit may help keep your memory sharp.

A new study shows caffeine reversed memory loss in mice bred to develop Alzheimer’s disease and reduced the level of beta-amyloid protein in the blood and brain. Plaques containing beta-amyloid protein are found in the brains of people with Alzheimer’s disease.

"The new findings provide evidence that caffeine could be a viable 'treatment' for established Alzheimer's disease, and not simply a protective strategy," researcher Gary Arendash, PhD, a neuroscientist at the University of South Florida, says in a news release. "That's important because caffeine is a safe drug for most people, it easily enters the brain, and it appears to directly affect the disease process."

Caffeine Reduces Memory Loss

In the study, mice bred to develop symptoms of Alzheimer’s disease were given 500 milligrams of caffeine (equivalent to five cups of regular coffee) in their daily drinking water once they started developing memory problems at age 18 to 19 months, about age 70 in human years.

After two months, the mice that drank the caffeinated water performed much better on tests of their memory and thinking skills -- to the level of normal mice of the same age. Those given plain water continued to do poorly on these tests. The study also showed that the brains of the caffeinated mice experienced a nearly 50% reduction in the level of beta-amyloid.

The researchers also looked at long-term caffeine treatment in normal mice. With 10 months of caffeine treatment, there was no improvement in memory and thinking skills.

Based on these findings, published in the Journal of Alzheimer’s Disease, Arendash and colleagues say they plan to start human trials to see whether caffeine can benefit people with early signs of Alzheimer’s disease.

日期:2009年7月7日 - 来自[Health News]栏目

Contrave: New Weight Loss Drug Advances

June 8, 2009 - A new weight loss drug looks good in late-stage clinical trials.

The drug is Contrave, from Orexigen Therapeutics Inc. It's a combination of two existing drugs: The antidepressant Wellbutrin and the addiction drug naltrexone.

Contrave doesn't work in the belly. It works in the hypothalamus, the brain's central thermostat that controls appetite, temperature, and how the body burns energy.

It's already known that people lose weight soon after starting Wellbutrin treatment. But this effect soon wears off, and people regain weight. That's where the naltrexone comes in, says endocrinologist Dennis D. Kim, MD, MBA, Orexigen's senior vice president for medical affairs.

"Naltrexone comes in and lifts the brake on the Wellbutrin effect," Kim tells WebMD. "So you have a synergistic effect to signal the hypothalamus to reduce food intake. Weight decrease is maintained over time."

That sounds good in theory. But does it work?

The drug was tested in a clinical trial that enrolled nearly 700 obese people -- 90% of them women, with an average weight of 223 pounds. All study participants enrolled in an intensive weight loss program that included counseling, diet, and exercise. Two-thirds of the study participants also took Contrave.

Just under 60% of the participants stayed in the program for 56 weeks.

The intensive weight loss program worked well. After 56 weeks, they had an overall weight loss of just over 5% of their body weight -- 11 to 16 pounds. Moreover, 11% of participants who finished the study lost more than 15% of their body weight.

But those who took Contrave did even better. After 56 weeks, they lost 9.3% of their body weight -- 20 to 25 pounds. And more than 29% of them lost more than 15% of their body weight.

Nausea, usually mild or moderate, was a frequent side effect of Contrave treatment. More patients on Contrave also reported mild-to-moderate headaches and constipation. All these side effects tended to occur early in the study.

Despite the side effects, patients on Contrave did not suffer worsening depression or psychiatric symptoms. In fact, they reported better quality of life than other participants.

Clearly, any weight loss drug will work better when combined with a state-of-the-art weight loss program. Additional studies are looking at how well Contrave works when combined with less drastic programs.

"We don't expect an intensive diet and exercise program to be needed in order for Contrave to work well," Kim says.

Contrave isn't the only weight loss drug Orexigen has in the works. The company is also testing another pill, Empatic, that combines Wellbutrin with the seizure drug Zonegran. In early clinical studies, obese patients lost 10% of their body weight in six months. More study results should be available by the end of this year.

Thomas Waden, PhD, of the University of Pennsylvania's Center for Weight and Eating Disorders, presented the Orexigen study findings in a presentation to the annual meeting of the American Diabetes Association, held June 6-9 in New Orleans.

日期:2009年6月9日 - 来自[Health News]栏目

Job Loss? Watch Your Health

May 8, 2009 -- Health can take a turn for the worse after job loss, a new report shows.

The report comes from Kate Strully, PhD, of the sociology department at New York's University of Albany.

While doing research at the Harvard School of Public Health as a Robert Wood Johnson Foundation scholar, Strully studied U.S. government health and employment data on 8,125 workers studied in 1999, 2001, and 2003.

Strully focused on people with no pre-existing health conditions, and on certain medical conditions -- such as heart disease, high blood pressure, arthritis, diabetes, and emotional or psychiatric problems -- that might be sensitive to stressful events like losing a job.

Strully also considered why workers lost their jobs -- whether they were downsized, fired, quit, or were let go because their workplace closed down.

Compared to people with steady jobs, people who lost their jobs because their workplace closed were 83% more likely to report a new health condition.

By the same comparison, getting fired or downsized was linked to a 43% increase in the odds of reporting a new health condition.

The findings held regardless of age, gender, race, and education. Other factors -- like diet, exercise, and family medical history -- weren't part of the study.

Losing a job can affect health, and not just because of financial strain or losing health insurance. It can also hurt workers' social network and social status, Strully notes.

Strully's findings appear in the May 8 issue of Demography.

?

日期:2009年5月9日 - 来自[Health News]栏目

34 Weight Loss Products Recalled

April 22, 2009 -- Universal ABC Beauty Supply International Inc. of Brooklyn, N.Y., is recalling 34 weight loss products because FDA tests show they contain sibutramine, the active ingredient in the appetite suppressant Meridia.

Meridia, which is FDA approved, isn't being recalled.

The recalled weight loss products aren't FDA approved and their labels don't note that they contain sibutramine.

"FDA advises that these products may pose a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke," states a news release from Universal ABC Beauty Supply International.

Here is the list of products that are being recalled:

1. ProSlim Plus, 60 capsules, bottle in box
2. 3 DAYS fit, 60 capsules, bottle in box
3. EIGHT FACTOR DIET, 60 capsules, 3 pouches/box
4. 24hours Diet, 60 capsules
5. Slim 3in1 M-18 ROYAL DIET, 90 capsules, 3 pouches/box
6. 3X SLIMMING POWER, 60 capsules, bottle in box
7. Extrim Plus 24 Hours RE-BURN Formula, 60 capsules
8. Slim 3in1 EXTRA SLIM FORMULA, 90 capsules, 3 pouches/box
9. Slim 3in1 EXTRA SLIM WAIST FORMULA, 90 capsules, 3 pouches/box
10. SLIM EXPRESS 360o C
11. SLIM EXPRESS 4in1, 60 capsules, bottle in box
12. ROYAL SLIMMING FORMULA, 60 capsules, bottle/box
13. BODY CREATOR, 90 capsules, 3 pouches/box
14. Slim Waistline (labeling written in Chinese)
15. BODY SHAPING, 90 capsules, 3 pouches/box
16. PERFECT SLIM, 90 capsules, 3 pouches/box
17. Perfect Slim 100% Natural Herbal Essence
18. IMELDA Perfect Slim
19. Slim Waist Formula, 32 capsules, 2 pouches/box
20. Super Slimming, 60 capsules, bottle in box
21. 2 DAY DIET
22. Powerful Slim
23. BODY SHAPING
24. SUPER FAT BURNER, 60 capsules, bottle in box
25. SLIMMING FORMULA
26. SLIM FAST 2, 32 capsules, 2 pouches/box
27. SLIM FAST, 60 capsules, 3 pouches/box
28. Slim up, 120 capsules, bottle in box
29. 7 DAYS DIET, 60 capsules, 3 pouches/box
30. Perfect Slim Up, 60 capsules, bottle in box
31. JM Fat Reducer
32. SlimBurn
33. 21 Double SLIM
34. TRIM PLUS 2

Universal ABC Beauty Supply International states that it's discontinuing the recalled products and hasn't received any reports of illness or injury linked to those products.

If you have any of the recalled products, don't use them. Return them to the place of purchase for a full refund or a partial refund of the unused pills.

Universal ABC Beauty Supply International advises consumers with questions to call Sandra Tan at 718-891-6888, Monday through Friday between noon and 6 p.m. Eastern time.

日期:2009年4月24日 - 来自[Health News]栏目

Study: No Vision Loss From ED Drugs

April 13, 2009 -- Using erectile dysfunction (ED) drugs like Viagra and Cialis for six months shouldn't lead to vision loss, according to a new study.

Researchers say concerns have been raised about possible vision-related side effects associated with regular use of ED drugs. But their study showed no higher rates of vision loss or other eye complications among men who took Viagra or Cialis daily for six months.

Viagra and Cialis are part of a group of drugs known as selective phosphodiesterase type 5 (PDE5) inhibitors that treat erectile dysfunction by interfering with the action of PDE5 on the blood vessels in the penis.

Researchers say concerns have risen about possible long-term vision-related side effects of PDE5 inhibitors because they may also act on similar compounds in the retina, the part of the eye that receives and transmits images. Levitra is another PDE5 inhibitor drug used for ED, but was not used in this study.

Men taking these drugs have also reported cases of blurred vision, blue-tinged vision, and altered light perception.

In the study, published in the Archives of Ophthalmology, researchers randomly assigned 244 healthy men age 30 to 65, some with mild erectile dysfunction, to take a daily dose of 5 milligrams of Cialis, 50 milligrams of Viagra, or a placebo for six months.

The men had comprehensive vision exams at the beginning and at the end of the study, including electroretinography (ERG, a test used to detect diseases of the retina).

The results showed no significant differences between those who took the erectile dysfunction drugs or the placebo on ERG, vision function tests, pressure within the eyeball, or assessments of the anatomy of the eye.

"PDE5 inhibitors can exert direct effects on the retina, and such effects probably account for many of the visual side effects such as blue-tinged vision and light sensitivity that have been reported," writes study researcher William H. Cordell, MD of Lilly Research Laboratories, Eli Lilly and Company, which manufactures Cialis and supported the study. However, "our results indicate that there is no cumulative damage or effect of clinical significance for either 5 milligrams of tadalafil [Cialis] or 50 milligrams of sildenafil [Viagra] taken daily for six months."

sex & relationships newsletter

Sex matters. See how to keep your relationship strong, your sex-life hot and your staying power intact. Sign up for the WebMD Sex & Relationships newsletter.

日期:2009年4月14日 - 来自[Health News]栏目
共 17 页,当前第 4 页 9 1 2 3 4 5 6 7 8 9 10 11 :


关闭

网站地图 | RSS订阅 | 图文 | 版权说明 | 友情链接
Copyright © 2008 39kf.com All rights reserved. 医源世界 版权所有 苏ICP备12067730号-1
医源世界所刊载之内容一般仅用于教育目的。您从医源世界获取的信息不得直接用于诊断、治疗疾病或应对您的健康问题。如果您怀疑自己有健康问题,请直接咨询您的保健医生。医源世界、作者、编辑都将不负任何责任和义务。
本站内容来源于网络,转载仅为传播信息促进医药行业发展,如果我们的行为侵犯了您的权益,请及时与我们联系我们将在收到通知后妥善处理该部分内容
联系Email: